2 results match your criteria: "Oklahoma University HSC[Affiliation]"
Vancomycin dosing in critically ill trauma patients: The VANCTIC Study.
J Trauma Acute Care Surg
November 2019
From the College of Pharmacy (R.D.V., S.N.), College of Medicine (O.T., A.C., A.C., R.K.), Oklahoma University HSC; and OU Medical Center (B.W.), Oklahoma City, Oklahoma.
Background: Current guidelines from the Infectious Diseases Society of America and the American Society of Health-System Pharmacists recommend vancomycin troughs of 15 mg/L to 20 mg/L for serious methicillin-resistant Staphylococcus aureus infections. The pharmacokinetics of vancomycin are altered in critically ill patients, leading to inadequate serum levels. Rates of initial therapeutic vancomycin troughs have ranged from 17.
View Article and Find Full Text PDFA phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Cancer Chemother Pharmacol
October 2015
Stephenson Cancer Center, Oklahoma University HSC, Oklahoma City, OK, USA.
Purpose: To characterize the cardiovascular safety profile of regorafenib in patients with advanced cancer.
Methods: Patients received regorafenib 160 mg/day for 21 days followed by a 7-day break. The primary endpoint was the change from baseline in QTcF at the regorafenib t(max) (Day 21, Cycle 1 or 2) and changes in left ventricular ejection fraction (LVEF) from baseline on Cycle 2, Day 21.